印度5岁及以下儿童侵袭性肺炎链球菌病的血清型分布与抗菌药物敏感性模式:系统综述
本系统综述纳入印度1990年1月至2016年12月发表的7项医院观察性研究,分析5岁及以下儿童侵袭性肺炎链球菌病的血清型分布与耐药情况。最常见的血清型为14、1、19F、6B、5、6A、9V和23F,现有PCV覆盖其中67.3%–78.4%。对甲氧苄啶/磺胺甲噁唑、红霉素、青霉素、氯霉素、左氧氟沙星和头孢噻肟的耐药率分别为81%、37%、10%、8%、6%和4%,未见万古霉素耐药报告。
要点
- 印度5岁及以下儿童侵袭性肺炎链球菌病最常见血清型为14、1、19F、6B、5、6A、9V和23F。
- 现有PCV制剂覆盖印度儿童侵袭性肺炎链球菌病血清型的67.3%–78.4%。
- 对甲氧苄啶/磺胺甲噁唑耐药率为81%、红霉素37%、青霉素10%、氯霉素8%、左氧氟沙星6%、头孢噻肟4%,未见万古霉素耐药报告。
核心结论
- 本综述显示,印度5岁及以下儿童报告的侵袭性肺炎链球菌病中,高达78.4%由现有已许可PCV所含血清型引起。
- 作者提出,必须在印度具有代表性的地区继续开展哨点监测,以评估肺炎链球菌血清型分布的变化趋势及其对疫苗选择和推广的意义。
研究设计与样本
- 系统文献综述,检索印度1990年1月至2016年12月发表的英文医院观察性研究(含同行评议文献和灰色文献)。
- 纳入记录5岁及以下儿童肺炎链球菌血清型分布和抗菌药物耐药模式数据的研究。
- 共筛查116项研究,排除109项,最终分析纳入7项研究。
主要发现
- 5岁及以下儿童侵袭性肺炎链球菌病最常见的血清型为14、1、19F、6B、5、6A、9V和23F。
- 在所综述文献涉及的大多数地理区域中,血清型14和19A均有报告。
- 当前可用的PCV制剂覆盖印度5岁及以下儿童侵袭性肺炎链球菌病全部血清型的67.3%–78.4%。
- 肺炎链球菌分离株对甲氧苄啶/磺胺甲噁唑、红霉素、青霉素、氯霉素、左氧氟沙星和头孢噻肟的耐药率分别为81%、37%、10%、8%、6%和4%。
- 未报告万古霉素耐药。
临床怎么用
- 作者提出,必须在印度具有代表性的地区继续开展哨点监测,以评估肺炎链球菌血清型分布的变化趋势及其对疫苗选择和推广的意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Streptococcus pneumoniae is a leading cause of childhood diseases that result in significant morbidity and mortality in India. Commercially licensed and available pneumococcal conjugate vaccines (PCVs) include ten (PCV-10) and 13 (PCV-13) pneumococcal serotypes. Vaccines with other serotype combinations are under development. Reviewing and reporting trends and distribution of pneumococcal serotypes causing invasive pneumococcal disease in India will be useful for policy making as PCV is being introduced into India's universal immunization program. METHODS: We conducted a systematic literature review of hospital based observational studies (both peer reviewed and gray literature published in English) from India available from January 1990 to December 2016. Studies that documented data on the prevalence of serotype distribution and the antimicrobial resistance pattern of S. pneumoniae in children≤5years of age were included. RESULT: We screened a total number of 116 studies, of which 109 studies were excluded. Final analysis included seven studies. The most frequent pneumococcal serotypes causing invasive disease among children≤5years were 14, 1, 19F, 6B, 5, 6A, 9V and 23F. Serotype 14 and 19A were represented in most of the geographical regions studied in the reviewed articles. Currently available PCV formulations included 67.3-78.4% of all serotypes contributing to IPD among Indian children≤5years. Pneumococcal resistance to trimethoprim/sulfamethoxazole, erythromycin, penicillin, chloramphenicol, levofloxacin and cefotaxime was seen in 81%, 37%, 10%, 8%, 6% and 4% of all pneumococcal isolates respectively, while vancomycin resistance was not reported. CONCLUSION: The present review demonstrates that up to 78.4% of reported invasive pneumococcal disease in children≤5years in India are currently caused by serotypes that are included in the available licensed PCVs. However, sentinel surveillance must be continued in representative parts of the country to assess the changing trends in distribution of pneumococcal serotypes and their implication for vaccine selection and rollout in India.
引用
- Singh J, Sundaresan S, Manoharan A, et al. Serotype distribution and antimicrobial susceptibility pattern in children≤5years with invasive pneumococcal disease in India - A systematic review. Vaccine. 2017. PMID: 28711387. doi:10.1016/j.vaccine.2017.06.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。